Description
Retatrutide is an investigational once-weekly triple-receptor agonist injection developed for obesity, type 2 diabetes, and related metabolic conditions. Unlike dual or single receptor drugs (like Zepbound or Ozempic), it simultaneously targets GLP-1, GIP, and glucagon receptors to suppress appetite and increase energy expenditure, yielding up to ~29% average weight loss in clinical trials.
How Retatrutide Works
- GLP-1 receptor: Slows stomach emptying and decreases hunger signals in the brain.
- GIP receptor: Enhances insulin secretion and improves how the body handles nutrients.
- Glucagon receptor: Stimulates energy expenditure (calorie burning) to boost fat loss.
